Journal article
MEDULLOBLASTOMA
Abstract
BACKGROUND: LMD in children with recurrent medulloblastoma and other PNETs carries a poor prognosis and novel therapies are urgently needed to improve disease control. Somatostatin receptor-2 (SSR-2)is overexpressed in medulloblastoma and other central PNETs and can serve as a target for radionuclide tagged somatostatin analogues like 177Lu-DOTA-TATE that has shown considerable efficacy in adults with SSR-2 positive neuro-endocrine tumors. As a …
Authors
Morfouace M; Shelat A; Megan J; Freeman BB; Robinson S; Throm S; Olson JM; Li X-N; Guy KR; Robinson G
Journal
Neuro-oncology, Vol. 16, No. Suppl 1, pp. i71–i96
Publication Date
June 2014
ISSN
1522-8517